Maxime Dely: CAR T Cell Therapy Starts With Collection
Maxime Dely, Sales and Application Specialist in Therapeutic Apheresis and Cell Therapy, shared a post on LinkedIn:
“Before CAR T, there is the collection.
CAR T cell therapy begins well before the genetic modification of T cells: it starts with eukapheresis, which collects the patient’s mononuclear cells, including the T lymphocytes that will be used to manufacture the cellular product.
This first step is critical: cell composition, viability and collection quality can influence the subsequent manufacturing process.
Apheresis technology is essential, but it is not enough. Successful collection also relies on the expertise, experience and vigilance of nurses, who adapt the procedure to each patient.
Before manufacturing CAR T cells, we first need to successfully collect them.”
Stay updated with Hemostasis Today.
-
Nov 20, 2026, 14:02Hasan Burak İşleyen։ Thrombocytopenia and Mortality in Critically Ill Cancer Patients
-
Nov 20, 2026, 13:50Louise Maes: CONVINCE Trial Imaging Studies Reveal New Insights Into Carotid Plaque and Vascular Risk
-
Nov 20, 2026, 13:50Lara Kurdi: A Presentation of Triple-Positive Antiphospholipid Syndrome
-
Nov 20, 2026, 13:46Rahul Bohra: Beyond Platelet Counts – The Lived Experience of ITP
-
Nov 20, 2026, 13:34Yohei Hisada: How Well Do Mouse Leukemia Models Reflect Human Disease?
-
Nov 20, 2026, 13:20Ilenia Calcaterra: The Inferior Thyroid Arteries as a Window Into Cardiovascular Risk
-
Nov 20, 2026, 13:03Does Being Fit Protect Against VTE? – RPTH Journal
-
Nov 20, 2026, 12:29Thirunavukkarasu Angappan: Antithrombin in ECMO – Two Datasets, Two Opposite Answers
-
Nov 20, 2026, 11:38Muhammad Kashif: Therapeutic Plasma Exchange – Key Concepts at a Glance